N-(Phosphonacetyl)-l-aspartate (PALA) in advanced malignant melanoma: A phase II trial of the EORTC malignant melanoma cooperative group (Q72774195)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6217975%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

title

N-(phosphonacetyl)-L-aspartate (PALA) in advanced malignant melanoma: a phase II trial of the EORTC Malignant Melanoma Cooperative Group (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6217975%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

N-(Phosphonacetyl)-l-aspartate (PALA) in advanced malignant melanoma: A phase II trial of the EORTC malignant melanoma cooperative group (English)

1 reference

https://api.crossref.org/works/10.1016/0277-5379(82)90069-4

31 August 2023

main subject

phase II clinical trial

1 reference

1 reference

https://api.crossref.org/works/10.1016/0277-5379(82)90069-4

31 August 2023

author name string

U. R. Kleeberg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6217975

31 August 2023

J. H. Mulder

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6217975

31 August 2023

P. Rümke

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6217975

31 August 2023

D. Thomas

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6217975

31 August 2023

M. Rozencweig

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6217975

31 August 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6217975

31 August 2023

publication date

1 August 1982

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6217975%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

29 October 2019

https://api.elsevier.com/content/article/PII:0277537982900694?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0277-5379(82)90069-4

https://api.elsevier.com/content/article/PII:0277537982900694?httpAccept=text/plain

31 August 2023

1 reference

https://api.crossref.org/works/10.1016/0277-5379(82)90069-4

European Journal of Cancer & Clinical Oncology

31 August 2023

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6217975%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6217975%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6217975%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

page(s)

723-726

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6217975%20AND%20SRC:MED&resulttype=core&format=json

Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-L-aspartate by uridine or carbamyl-DL-asparate in vivo

29 October 2019

cites work

2

1 reference

https://api.crossref.org/works/10.1016/0277-5379(82)90069-4

Stable mutants of mammalian cells that overproduce the first three enzymes of pyrimidine nucleotide biosynthesis

31 August 2023

6

1 reference

https://api.crossref.org/works/10.1016/0277-5379(82)90069-4

Phase I trial of N-(phosphonacetyl)-L-aspartate

31 August 2023

8

1 reference

https://api.crossref.org/works/10.1016/0277-5379(82)90069-4

Phase I study of N-(phosphonacetyl)-L-aspartic acid (PALA)

31 August 2023

10

1 reference

https://api.crossref.org/works/10.1016/0277-5379(82)90069-4

31 August 2023

Phase I trial of PALA

11

1 reference

https://api.crossref.org/works/10.1016/0277-5379(82)90069-4

Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA)

31 August 2023

12

1 reference

https://api.crossref.org/works/10.1016/0277-5379(82)90069-4

Initial clinical study with N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with advanced cancer

31 August 2023

13

1 reference

https://api.crossref.org/works/10.1016/0277-5379(82)90069-4

Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA)

31 August 2023

14

1 reference

https://api.crossref.org/works/10.1016/0277-5379(82)90069-4

Phase II evaluation of PALA and AMSA for patients with disseminated malignant melanoma

31 August 2023

15

1 reference

https://api.crossref.org/works/10.1016/0277-5379(82)90069-4

N-(Phosphonacetyl)-l-aspartate (PALA) in advanced soft tissue sarcoma: a phase II trial of the EORTC soft tissue sarcoma group

31 August 2023

16

1 reference

https://api.crossref.org/works/10.1016/0277-5379(82)90069-4

N-(Phosphonacetyl)-l-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group

31 August 2023

17

1 reference

https://api.crossref.org/works/10.1016/0277-5379(82)90069-4

Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum

31 August 2023

18

1 reference

https://api.crossref.org/works/10.1016/0277-5379(82)90069-4

Phase II study of PALA in advanced large bowel carcinoma

31 August 2023

20

1 reference

https://api.crossref.org/works/10.1016/0277-5379(82)90069-4

Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung

31 August 2023

21

1 reference

https://api.crossref.org/works/10.1016/0277-5379(82)90069-4

Phase II evaluation of PALA in patients with metastatic lung cancer

31 August 2023

22

1 reference

https://api.crossref.org/works/10.1016/0277-5379(82)90069-4

31 August 2023

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6217975%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

1 reference